Clinical Endpoint Study of Ivermectin 1% Cream

Summary

A randomized, double-blind, placebo-controlled, parallel-design, multiple-site clinical study to evaluate the therapeutic equivalence and safety of ivermectin cream 1% (Actavis Laboratories UT, Inc.) to SoolantraTM (ivermectin) cream 1% (Galderma) in the treatment of moderate to severe papulopustular rosacea.

Timeline

Start

2016-06

Primary completion

2016-11

Completion

2016-12

Drugs

Indications